• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Intersect ENT, Inc.

    10/20/21 4:41:21 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care
    Get the next $XENT alert in real time by email
    SC 13G 1 Xent_SC13G.htm SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934

    INTERSECT ENT, INC.
    (Name of Issuer)

    COMMON STOCK, PAR VALUE $0.001 PER SHARE
    (Title of Class of Securities)

    46071F103
    (CUSIP Number)

    OCTOBER 11, 2021
    (Date of event which requires filing of this statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

         o Rule 13d-1(b)

         þ Rule 13d-1(c)

         o Rule 13d-1(d)

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).



                         
    CUSIP No.
     
    46071F103

    SCHEDULE 13G

    Page  
    2
      of   
    16

    1
     NAMES OF REPORTING PERSONS
     
     Integrated Core Strategies (US) LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     1,338,592
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     1,338,592
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,338,592
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     4.0%
    12 TYPE OF REPORTING PERSON

     OO


                         
    CUSIP No.
     
    46071F103

    SCHEDULE 13G

    Page  
    3
      of   
    16

    1
     NAMES OF REPORTING PERSONS
     
     ICS Opportunities II LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     60,773
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     60,773
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     60,773
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.2%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    46071F103

    SCHEDULE 13G

    Page  
    4
      of   
    16

    1
     NAMES OF REPORTING PERSONS
     
     ICS Opportunities, Ltd.
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     230,068
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     230,068
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     230,068
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.7%
    12 TYPE OF REPORTING PERSON

     
    CO


                         
    CUSIP No.
     
    46071F103

    SCHEDULE 13G

    Page  
    5
      of   
    16

    1
     NAMES OF REPORTING PERSONS
     
     Integrated Assets, Ltd.
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     735
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     735
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     735
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.0%
    12 TYPE OF REPORTING PERSON

     
    CO


                         
    CUSIP No.
     
    46071F103

    SCHEDULE 13G

    Page  
    6
      of   
    16

    1
     NAMES OF REPORTING PERSONS
     
     Millennium International Management LP
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     291,576
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     291,576
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     291,576
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.9%
    12 TYPE OF REPORTING PERSON

     
    PN


                         
    CUSIP No.
     
    46071F103

    SCHEDULE 13G

    Page  
    7
      of   
    16

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     1,630,168
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     1,630,168
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,630,168
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     4.9%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    46071F103

    SCHEDULE 13G

    Page  
    8
      of   
    16

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Group Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     1,630,168
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     1,630,168
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,630,168
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     4.9%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    46071F103

    SCHEDULE 13G

    Page  
    9
      of   
    16

    1
     NAMES OF REPORTING PERSONS
     
     Israel A. Englander
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     1,630,168
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     1,630,168
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,630,168
    10
     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     4.9%
    12
     TYPE OF REPORTING PERSON

     IN

                         
    CUSIP No.
     
    46071F103

     SCHEDULE 13G

    Page  
    10
      of   
    16
     
    Item 1.    
     
    (a) Name of Issuer:
     
       
     
      Intersect ENT, Inc., a Delaware corporation (the "Issuer").
     
       
     
    (b) Address of Issuer’s Principal Executive Offices:
     
       
     
     

    1555 Adams Drive
    Menlo Park, California 94025

         
    Item 2.
    (a) Name of Person Filing:
     
    (b) Address of Principal Business Office:
     
    (c) Citizenship:
         
     
      Integrated Core Strategies (US) LLC
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      ICS Opportunities II LLC
    c/o Millennium International Management LP
    399 Park Avenue
    New York, New York 10022
    Citizenship: Cayman Islands
     
       
     
      ICS Opportunities, Ltd.
    c/o Millennium International Management LP
    399 Park Avenue
    New York, New York 10022
    Citizenship: Cayman Islands
     
       
     
      Integrated Assets, Ltd.
    c/o Millennium International Management LP
    399 Park Avenue
    New York, New York 10022
    Citizenship: Cayman Islands
     
       
     
      Millennium International Management LP
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Group Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Israel A. Englander
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: United States
     
       
      (d) Title of Class of Securities:
    common stock, par value $0.001 per share ("Common Stock")
     
      (e) CUSIP Number:
         
        46071F103


                         
    CUSIP No.
     
    46071F103

    SCHEDULE 13G

    Page  
    11
      of   
    16

    Item 3.  If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     
      (a)   o   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
                 
     
      (b)   o   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
                 
     
      (c)   o   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
                 
     
      (d)   o   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
                 
     
      (e)   o   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
                 
     
      (f)   o    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

                         
    CUSIP No.
     
    46071F103

     SCHEDULE 13G

    Page  
    12
      of   
    16
                 
     
      (g)   o   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
                 
     
      (h)   o   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
                 
     
      (i)   o   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
                 
     
      (j)   o   Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4. Ownership

       Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount Beneficially Owned

       As of the close of business on October 11, 2021, the reporting persons beneficially owned an aggregate of 1,770,469 shares of the Issuer’s Common Stock or 5.3% of the Issuer’s Common Stock outstanding.

       Thereafter, as of the close of business on October 19, 2021:

       i) Integrated Core Strategies (US) LLC, a Delaware limited liability company ("Integrated Core Strategies"), beneficially owned 1,338,592 shares of the Issuer’s Common Stock;

       ii) ICS Opportunities II LLC, a Cayman Islands limited liability company ("ICS Opportunities II"), beneficially owned 60,773 shares of the Issuer’s Common Stock;

       iii) ICS Opportunities, Ltd., an exempted company organized under the laws of the Cayman Islands ("ICS Opportunities"), beneficially owned 230,068 shares of the Issuer’s Common Stock; and

       iv) Integrated Assets, Ltd., an exempted company organized under the laws of the Cayman Islands ("Integrated Assets"), beneficially owned 735 shares of the Issuer’s Common Stock, which together with the shares of the Issuer’s Common Stock beneficially owned by Integrated Core Strategies, ICS Opportunities II and ICS Opportunities represented 1,630,168 shares of the Issuer’s Common Stock or 4.9% of the Issuer’s Common Stock outstanding.

       Millennium International Management LP, a Delaware limited partnership ("Millennium International Management"), is the investment manager to ICS Opportunities II, ICS Opportunities and Integrated Assets and may be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities II, ICS Opportunities and Integrated Assets.

       Millennium Management LLC, a Delaware limited liability company ("Millennium Management"), is the general partner of the managing member of Integrated Core Strategies and may be deemed to have shared voting control and investment discretion over securities owned by Integrated Core Strategies. Millennium Management is also the general partner of the 100% owner of ICS Opportunities II, ICS Opportunities and Integrated Assets and may also be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities II, ICS Opportunities and Integrated Assets.

       Millennium Group Management LLC, a Delaware limited liability company ("Millennium Group Management"), is the managing member of Millennium Management and may also be deemed to have shared voting control and investment discretion over securities owned by Integrated Core Strategies. Millennium Group Management is also the general partner of Millennium International Management and may also be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities II, ICS Opportunities and Integrated Assets.

       The managing member of Millennium Group Management is a trust of which Israel A. Englander, a United States citizen ("Mr. Englander"), currently serves as the sole voting trustee. Therefore, Mr. Englander may also be deemed to have shared voting control and investment discretion over securities owned by Integrated Core Strategies, ICS Opportunities II, ICS Opportunities and Integrated Assets.

       The foregoing should not be construed in and of itself as an admission by Millennium International Management, Millennium Management, Millennium Group Management or Mr. Englander as to beneficial ownership of the securities owned by Integrated Core Strategies, ICS Opportunities II, ICS Opportunities or Integrated Assets, as the case may be.

    (b) Percent of Class:   

       As of the close of business on October 19, 2021, Millennium Management, Millennium Group Management and Mr. Englander may be deemed to have beneficially owned 1,630,168 shares of the Issuer’s Common Stock or 4.9% of the Issuer’s Common Stock outstanding (see Item 4(a) above), which percentage was calculated based on 33,420,243 shares of the Issuer’s Common Stock outstanding as of September 3, 2021, as reported in the Issuer’s proxy statement filed on September 7, 2021.


                         
    CUSIP No.
     
    46071F103

     SCHEDULE 13G

    Page  
    13
      of   
    16

     (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote

       -0-

    (ii) Shared power to vote or to direct the vote

       1,630,168 (See Item 4(b))

     (iii) Sole power to dispose or to direct the disposition of

       -0-

    (iv) Shared power to dispose or to direct the disposition of

       1,630,168 (See Item 4(b))

    Item 5. Ownership of Five Percent or Less of a Class

       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following þ .

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

        Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

        Not applicable.

    Item 8. Identification and Classification of Members of the Group

        See Exhibit I.

    Item 9. Notice of Dissolution of Group

        Not applicable.

    Item 10. Certification 

       By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


                         
    CUSIP No.
     
    46071F103

    SCHEDULE 13G

    Page  
    14
      of   
    16

    Exhibits:

    Exhibit I: Joint Filing Agreement, dated as of October 19, 2021, by and among Integrated Core Strategies (US) LLC, ICS Opportunities II LLC, ICS Opportunities, Ltd., Integrated Assets, Ltd., Millennium International Management LP, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.


                         
    CUSIP No.
     
    46071F103

    SCHEDULE 13G

    Page  
    15
      of   
    16
                         
         

    SIGNATURE

                 

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

    Dated: October 19, 2021

    INTEGRATED CORE STRATEGIES (US) LLC

    By: Integrated Holding Group LP,
           its Managing Member

    By: Millennium Management LLC,
           its General Partner

    By: /s/ Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    ICS OPPORTUNITIES II LLC

    By: Millennium International Management LP,
           its Investment Manager

    By: /s/ Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    ICS OPPORTUNITIES, LTD.

    By: Millennium International Management LP,
           its Investment Manager

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    INTEGRATED ASSETS, LTD.

    By: Millennium International Management LP,
           its Investment Manager

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM INTERNATIONAL MANAGEMENT LP

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander



                         
    CUSIP No.
     
    46071F103

    SCHEDULE 13G

    Page  
    16
      of   
    16
                         
          EXHIBIT I              
                         
          JOINT FILING AGREEMENT              

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.001 per share, of Intersect ENT, Inc., a Delaware corporation, will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

    Dated: October 19, 2021

    INTEGRATED CORE STRATEGIES (US) LLC

    By: Integrated Holding Group LP,
           its Managing Member

    By: Millennium Management LLC,
           its General Partner

    By: /s/ Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    ICS OPPORTUNITIES II LLC

    By: Millennium International Management LP,
           its Investment Manager

    By: /s/ Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    ICS OPPORTUNITIES, LTD.

    By: Millennium International Management LP,
           its Investment Manager

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    INTEGRATED ASSETS, LTD.

    By: Millennium International Management LP,
           its Investment Manager

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM INTERNATIONAL MANAGEMENT LP

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander


    Get the next $XENT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XENT

    DatePrice TargetRatingAnalyst
    8/12/2021$28.25Outperform → Market Perform
    SVB Leerink
    8/10/2021Buy → Neutral
    BTIG
    8/9/2021$29.00 → $28.25Buy → Hold
    Canaccord Genuity
    8/9/2021$28.25Buy → Neutral
    Guggenheim
    6/24/2021$21.00 → $23.00Market Perform → Outperform
    SVB Leerink
    More analyst ratings

    $XENT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nalu Medical, Inc. Names Thomas West President and Chief Executive Officer

    Current President and CEO, Earl Fender, announces retirement CARLSBAD, Calif., July 14, 2022 /PRNewswire-PRWeb/ -- Nalu Medical, Inc. ("Nalu"), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today that the Board of Directors has appointed Thomas "Tom" West as President and Chief Executive Officer. This leadership appointment is effective on August 8th and follows the decision by Earl Fender, Nalu's current CEO, to retire. Mr. Fender will remain as a consultant to the company for the next 12 months. Mr. West remarked, "I am very excited and honored to be leading Nalu. I believe Nalu's unique system and technology, including the

    7/14/22 12:05:00 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Real-World Evidence Study Demonstrates Intersect ENT's PROPEL® Sinus Implant Reduces Healthcare Resource Utilization

    Data from first-of-its-kind study published in Current Medical Research and Opinion Patients receiving PROPEL® following endoscopic sinus surgery had statistically significant lower healthcare resource utilization over a postoperative period of 18 months, including all-cause otolaryngologist, ER/urgent care and outpatient visits, as well as sinus-related endoscopies Intersect ENT®, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced positive results of an observational, cohort study using real-world evidence (RWE) data from adult patients with chronic rhinosinusitis (CRS) with or without nasal polyps

    1/25/22 7:00:00 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Orthofix Announces Appointment of Thomas A. West to Board of Directors

    Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that Thomas A. West has been named to the Company's Board of Directors and appointed to the Compensation and Talent Development Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005343/en/Thomas A. West named to Orthofix Board of Directors and appointed to the Compensation and Talent Development Committee. (Photo: Business Wire) Mr. West currently serves as the President, Chief Executive Officer and Director of Intersect ENT, Inc. (NASDAQ:XENT), a commercial stage drug-device company that pioneers

    12/14/21 7:00:00 AM ET
    $OFIX
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Hattangadi Neil A

    4 - Intersect ENT, Inc. (0001271214) (Issuer)

    5/16/22 6:58:08 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Meier Richard A closing all direct ownership in the company

    4 - Intersect ENT, Inc. (0001271214) (Issuer)

    5/16/22 6:43:33 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Fernandez Reyna M closing all direct ownership in the company

    4 - Intersect ENT, Inc. (0001271214) (Issuer)

    5/16/22 6:41:18 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Intersect ENT downgraded by SVB Leerink with a new price target

    SVB Leerink downgraded Intersect ENT from Outperform to Market Perform and set a new price target of $28.25

    8/12/21 4:49:01 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Intersect ENT downgraded by BTIG

    BTIG downgraded Intersect ENT from Buy to Neutral

    8/10/21 5:09:28 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Intersect ENT downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Intersect ENT from Buy to Hold and set a new price target of $28.25 from $29.00 previously

    8/9/21 10:22:16 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SINUVA issued to INTERSECT ENT INC

    Submission status for INTERSECT ENT INC's drug SINUVA (SUPPL-6) with active ingredient MOMETASONE FUROATE has changed to 'Approval' on 01/20/2023. Application Category: NDA, Application Number: 209310, Application Classification: Labeling

    1/23/23 11:02:41 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    SEC Filings

    View All

    SEC Form POSASR filed by Intersect ENT Inc.

    POSASR - Intersect ENT, Inc. (0001271214) (Filer)

    9/12/22 5:25:28 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form RW WD filed by Intersect ENT Inc.

    RW WD - Intersect ENT, Inc. (0001271214) (Filer)

    9/12/22 1:10:59 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form 15-12B filed by Intersect ENT Inc.

    15-12B - Intersect ENT, Inc. (0001271214) (Filer)

    5/23/22 6:08:00 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    Financials

    Live finance-specific insights

    View All

    Intersect ENT Reports Third Quarter 2021 Financial Results

    Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today reported financial results for the third quarter ended September 30, 2021. Total revenue was $24.4 million for the third quarter of 2021, up 7%, compared to $22.7 million for the same period of 2020. Gross profit for the third quarter of 2021 was $19.3 million and gross margin was 79.2%, compared to gross profit of $14.9 million and gross margin of 65.5% for the same period of 2020. Excluding the impact of intangible asset amortization, adjusted gross profit and adjusted gross margin for the third quarter of 2021 was $19.8 million and 81.2%, resp

    11/2/21 4:15:00 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Intersect ENT Reports Second Quarter 2021 Financial Results

    Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today reported financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Overview Entered into a definitive agreement with Medtronic, in which Medtronic will acquire all outstanding shares of Intersect ENT. Revenue of $27.3 million in the second quarter of 2021, up 180%, compared to $9.8 million in the second quarter of 2020. Record quarterly SINUVA revenue of $2.7 million. Global Navigation and Balloon portfolio generated quarterly revenue of $1.6 million. Cash, cash equivalents, restricted cash, and short-term investm

    8/6/21 7:15:00 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Intersect ENT to Report Second Quarter 2021 Financial Results on August 6

    Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced that it will release second quarter 2021 financial results on Friday, August 6, 2021. The Company expects to issue the release at approximately 7:00 a.m. ET and management will host a conference call at 8:30 a.m. ET. To access the conference call via the Internet, go to the "Investor Relations" page of the Company's website at www.intersectENT.com. To access the live conference call via phone, dial 844-850-0548 and ask to join the Intersect ENT call. International callers may access the live call by dialing 412-317-5205. Participants may

    7/23/21 8:00:00 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Intersect ENT Inc. (Amendment)

    SC 13G/A - Intersect ENT, Inc. (0001271214) (Subject)

    2/23/22 8:56:48 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Intersect ENT Inc. (Amendment)

    SC 13G/A - Intersect ENT, Inc. (0001271214) (Subject)

    2/17/22 11:40:20 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Intersect ENT Inc. (Amendment)

    SC 13G/A - Intersect ENT, Inc. (0001271214) (Subject)

    2/14/22 4:41:22 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    Leadership Updates

    Live Leadership Updates

    View All

    Orthofix Announces Appointment of Thomas A. West to Board of Directors

    Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that Thomas A. West has been named to the Company's Board of Directors and appointed to the Compensation and Talent Development Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005343/en/Thomas A. West named to Orthofix Board of Directors and appointed to the Compensation and Talent Development Committee. (Photo: Business Wire) Mr. West currently serves as the President, Chief Executive Officer and Director of Intersect ENT, Inc. (NASDAQ:XENT), a commercial stage drug-device company that pioneers

    12/14/21 7:00:00 AM ET
    $OFIX
    $XENT
    Medical/Dental Instruments
    Health Care

    Intersect ENT Announces Appointment of New Vice President of Sales

    Mark L. Alley to serve as Vice President of Sales Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced the appointment of Mark L. Alley as Vice President of Sales, effective May 10, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210504005421/en/Mark L. Alley (Photo: Business Wire) Mr. Alley previously served as Chief Commercial Officer at medical device specialist Levita Magnetics Corp. He is a proven leader with over 20 years of commercial and sales success in companies ranging in size from start-ups to Fortune 500 compan

    5/4/21 7:00:00 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care